155 related articles for article (PubMed ID: 37607946)
41. Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.
Hwang BJ; Tsao LC; Acharya CR; Trotter T; Agarwal P; Wei J; Wang T; Yang XY; Lei G; Osada T; Lyerly HK; Morse MA; Hartman ZC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361727
[TBL] [Abstract][Full Text] [Related]
42. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
43. Apolipoprotein L3 enhances CD8+ T cell antitumor immunity of colorectal cancer by promoting LDHA-mediated ferroptosis.
Lv Y; Tang W; Xu Y; Chang W; Zhang Z; Lin Q; Ji M; Feng Q; He G; Xu J
Int J Biol Sci; 2023; 19(4):1284-1298. PubMed ID: 36923931
[No Abstract] [Full Text] [Related]
44. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.
Wang S; Kuai Y; Lin S; Li L; Gu Q; Zhang X; Li X; He Y; Chen S; Xia X; Ruan Z; Lin C; Ding Y; Zhang Q; Qi C; Li J; He X; Pathak JL; Zhou W; Liu S; Wang L; Zheng L
BMC Med; 2023 Mar; 21(1):115. PubMed ID: 36978108
[TBL] [Abstract][Full Text] [Related]
45. CXCL8 induces M2 macrophage polarization and inhibits CD8
Shao Y; Lan Y; Chai X; Gao S; Zheng J; Huang R; Shi Y; Xiang Y; Guo H; Xi Y; Yang L; Yang T
FASEB J; 2023 Oct; 37(10):e23173. PubMed ID: 37665572
[TBL] [Abstract][Full Text] [Related]
46. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
[TBL] [Abstract][Full Text] [Related]
47. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
Hijazi A; Antoniotti C; Cremolini C; Galon J
Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
[TBL] [Abstract][Full Text] [Related]
48. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
49. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
50. The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis.
Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106966. PubMed ID: 33182067
[TBL] [Abstract][Full Text] [Related]
51. Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy.
Zheng X; Gao Y; Yu C; Fan G; Li P; Zhang M; Yu J; Xu M
Sci Rep; 2021 Sep; 11(1):19432. PubMed ID: 34593914
[TBL] [Abstract][Full Text] [Related]
52. Integrated Profiling Identifies
Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
Front Immunol; 2021; 12():722807. PubMed ID: 34646265
[TBL] [Abstract][Full Text] [Related]
53. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
54. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
Wang Q; Shen X; Chen G; Du J
Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
[TBL] [Abstract][Full Text] [Related]
55. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
56. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
57. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
[TBL] [Abstract][Full Text] [Related]
58. Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
Breitenecker K; Homolya M; Luca AC; Lang V; Trenk C; Petroczi G; Mohrherr J; Horvath J; Moritsch S; Haas L; Kurnaeva M; Eferl R; Stoiber D; Moriggl R; Bilban M; Obenauf AC; Ferran C; Dome B; Laszlo V; Győrffy B; Dezso K; Moldvay J; Casanova E; Moll HP
Sci Transl Med; 2021 Jul; 13(601):. PubMed ID: 34233950
[TBL] [Abstract][Full Text] [Related]
59. Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy.
Li W; Wu Z; Meng W; Zhang C; Cheng M; Chen Y; Zou Y; Li K; Lin S; Xiong W; Wang Y; Lin Y; Ma W; Zhou W
Cytokine; 2022 Oct; 158():155976. PubMed ID: 35921790
[TBL] [Abstract][Full Text] [Related]
60. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
